Dynavax Technologies Corp (NASDAQ:DVAX) shares, rose in value on Wednesday, May 07, with the stock price down by -10.99% to the previous day’s close as strong demand from buyers drove the stock to $9.72. Actively observing the price movement in the last trading, the stock
Dynavax Technologies Corp. (NASDAQ: DVAX), a biotechnology company, has signed a contract to endow the company with the right to commercialize the hepatitis B vaccine in Germany and the EU in the future. Last week, Dynavax Technologies announced that it had entered into a collaboration
Stocks Register is a comprehensive online news hub delivering daily updates on various facets of U.S. life, including business, technology, politics, economy, culture, sports, and noteworthy global events.